Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Ginekologia Polska
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 89, No 9 (2018)
Research paper
Published online: 2018-09-28
View PDF Download PDF file
Get Citation

Does endocan level increase in women with polycystic ovary syndrome? A case — control study

Ilhan Bahri Delibas1, Omer Erkan Yapca2, Esra Laloglu3
DOI: 10.5603/GP.a2018.0085
·
Pubmed: 30318577
·
Ginekol Pol 2018;89(9):500-505.
Affiliations
  1. Department of Obstetrics and Gynecology, Gaziosmanpasa University, Tokat, Turkey
  2. Department of Obstetrics and Gynecology, Ataturk University, Erzurum, Turkey
  3. Erzurum Public Health Laboratory, Erzurum, Türkiye

open access

Vol 89, No 9 (2018)
ORIGINAL PAPERS Gynecology
Published online: 2018-09-28

Abstract

Objectives: To evaluate endocan levels of patients with polycystic ovary syndrome (PCOS) in comparison to healthy women.

Material and methods: A cross-sectional case-control study on 88 patients with PCOS (mean age, 22.06 ± 4.24 years; body mass index [BMI], 23.9 ± 4.74 kg/m2) and 87 age- and BMI-matched healthy women (mean age, 23.71 ± 4.42 years; BMI, 22.15 ± 3.03 kg/m2).

Results: Serum endocan level was significantly higher in PCOS group than control group (540.9 ± 280.3 pg/mL vs. 355.5 ± 233.5 pg/mL, respectively; p < 0.001). The presence of polycystic ovary finding on ultrasonography or oligomenorhea did not produce significant effect on serum endocan levels (p > 0.05). In PCOS group, endocan level was negatively correlated with BMI and C-reactive protein level, and positively correlated with high density lipoprotein level (p < 0.05).

Conclusions: Blood endocan level is increased in PCOS. Further studies are needed to evaluate the clinical value of blood endocan level as a marker for the risk of cardiovascular and metabolic diseases in patients with PCOS.

Abstract

Objectives: To evaluate endocan levels of patients with polycystic ovary syndrome (PCOS) in comparison to healthy women.

Material and methods: A cross-sectional case-control study on 88 patients with PCOS (mean age, 22.06 ± 4.24 years; body mass index [BMI], 23.9 ± 4.74 kg/m2) and 87 age- and BMI-matched healthy women (mean age, 23.71 ± 4.42 years; BMI, 22.15 ± 3.03 kg/m2).

Results: Serum endocan level was significantly higher in PCOS group than control group (540.9 ± 280.3 pg/mL vs. 355.5 ± 233.5 pg/mL, respectively; p < 0.001). The presence of polycystic ovary finding on ultrasonography or oligomenorhea did not produce significant effect on serum endocan levels (p > 0.05). In PCOS group, endocan level was negatively correlated with BMI and C-reactive protein level, and positively correlated with high density lipoprotein level (p < 0.05).

Conclusions: Blood endocan level is increased in PCOS. Further studies are needed to evaluate the clinical value of blood endocan level as a marker for the risk of cardiovascular and metabolic diseases in patients with PCOS.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

endocan, polycystic ovary syndrome, inflammation, case-control

About this article
Title

Does endocan level increase in women with polycystic ovary syndrome? A case — control study

Journal

Ginekologia Polska

Issue

Vol 89, No 9 (2018)

Article type

Research paper

Pages

500-505

Published online

2018-09-28

Page views

2490

Article views/downloads

1025

DOI

10.5603/GP.a2018.0085

Pubmed

30318577

Bibliographic record

Ginekol Pol 2018;89(9):500-505.

Keywords

endocan
polycystic ovary syndrome
inflammation
case-control

Authors

Ilhan Bahri Delibas
Omer Erkan Yapca
Esra Laloglu

References (35)
  1. Carmina E, Orio F, Palomba S, et al. Endothelial Dysfunction in PCOS: Role of Obesity and Adipose Hormones. The American Journal of Medicine. 2006; 119(4): 356.e1–356.e6.
    CrossRef
  2. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999; 22(1): 141–146.
    PubMed
  3. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999; 84(1): 165–169.
    CrossRefPubMed
  4. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001; 103(10): 1410–1415.
    PubMed
  5. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol. 2005; 152(5): 749–756.
    CrossRefPubMed
  6. Diamanti-Kandarakis E, Spina G, Kouli C, et al. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab. 2001; 86(10): 4666–4673.
    CrossRefPubMed
  7. Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001; 86(6): 2453–2455.
    CrossRefPubMed
  8. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod. 2006; 21(6): 1426–1431.
    CrossRefPubMed
  9. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol. 1999; 31(1): 23–37.
    CrossRefPubMed
  10. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2): 115–126.
    CrossRefPubMed
  11. Aparci M, Isilak Z, Uz O, et al. Endocan and endothelial dysfunction. Angiology. 2015; 66(5): 488–489.
    CrossRefPubMed
  12. Mihajlovic DM, Lendak DF, Brkic SV, et al. Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res. 2014; 93: 92–97.
    CrossRefPubMed
  13. Kao YH, Chiu WC, Hsu MI, et al. Endothelial progenitor cell dysfunction in polycystic ovary syndrome: implications fort he genesis of cardiovascular diseases. Int J Fert Steril. 2013; 6: 208–213.
  14. Bicer M, Guler A, Unal Kocabas G, et al. Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. Endocr Res. 2017; 42(2): 145–153.
    CrossRefPubMed
  15. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
    PubMed
  16. FERRIMAN D, GALLWEY JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961; 21: 1440–1447.
    CrossRefPubMed
  17. Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41(4): 1149–1160.
    CrossRefPubMed
  18. Kali A, Shetty KS. Endocan: a novel circulating proteoglycan. Indian J Pharmacol. 2014; 46(6): 579–583.
    CrossRefPubMed
  19. Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014; 70(2): 291–296.
    CrossRefPubMed
  20. Saldir M, Tunc T, Cekmez F, et al. Endocan and Soluble Triggering Receptor Expressed on Myeloid Cells-1 as Novel Markers for Neonatal Sepsis. Pediatr Neonatol. 2015; 56(6): 415–421.
    CrossRefPubMed
  21. Celık T, Balta S, Karaman M, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2015; 24(1): 55–60.
    CrossRefPubMed
  22. Zuwala-Jagiello J, Simon K, Kukla M, et al. Increased circulating endocan in patients with cirrhosis: relation to bacterial infection and severity of disease. J Physiol Pharmacol. 2017; 68(2): 273–282.
    PubMed
  23. Laloglu E, Kumtepe Y, Aksoy H, et al. Serum endocan levels in endometrial and ovarian cancers. J Clin Lab Anal. 2017; 31(5).
    CrossRefPubMed
  24. Schuitemaker JHN, Cremers TI, Van Pampus MG, et al. Changes in endothelial cell specific molecule 1 plasma levels during preeclamptic pregnancies compared to healthy pregnancies. Pregnancy Hypertens. 2018; 12: 58–64.
    CrossRefPubMed
  25. Samy N, Hashim M, Sayed M, et al. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers. 2009; 26(4): 163–170.
    CrossRefPubMed
  26. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006; 1765(1): 25–37.
    CrossRefPubMed
  27. Lee W, Ku SK, Kim SW, et al. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014; 229(5): 620–630.
    CrossRefPubMed
  28. Zafari Zangeneh F, Naghizadeh MM, Masoumi M. Polycystic ovary syndrome and circulating inflammatory markers. Int J Reprod Biomed (Yazd). 2017; 15(6): 375–382.
    PubMed
  29. Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011; 95(3): 1048–10458.e1.
    CrossRefPubMed
  30. Rajendran S, Willoughby SR, Chan WP, et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis. 2009; 204(2): 509–514.
    CrossRefPubMed
  31. Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2011; 335(1): 30–41.
    CrossRefPubMed
  32. Balta S, Mikhailidis DP, Demirkol S, et al. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosclerosis. 2015; 243(1): 339–343.
    CrossRefPubMed
  33. Cox LAE, van Eijk LT, Ramakers BPC, et al. Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock. 2015; 43(4): 322–326.
    CrossRefPubMed
  34. Mohlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. European Journal of Endocrinology. 2004; 150(4): 525–532.
    CrossRef
  35. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259(5091): 87–91.
    PubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl